Pfizer Forecast, price target & analysts
Pfizer Target price 2025 - Analyst rating & recommendation
Pfizer Classifications & Recommendation:
Pfizer Price Target
| Target Price | $30.39 |
| Price | $25.99 |
| Potential |
16.93%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Pfizer 2026 .
The average Pfizer target price is $30.39.
This is
16.93%
register free of charge
$36.00
38.51%
register free of charge
$25.00
3.81%
register free of charge
|
|
| A rating was issued by 23 analysts: 9 Analysts recommend Pfizer to buy, 13 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pfizer stock has an average upside potential 2026 of
16.93%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 63.63 | 62.95 |
| 6.84% | 1.07% | |
| EBITDA Margin | 36.93% | 38.40% |
| 89.88% | 3.99% | |
| Net Margin | 12.56% | 19.98% |
| 256.68% | 59.10% |
18 Analysts have issued a sales forecast Pfizer 2025 . The average Pfizer sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Pfizer EBITDA forecast 2025. The average Pfizer EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Pfizer Analysts have issued a net profit forecast 2025. The average Pfizer net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.41 | 2.22 |
| 281.08% | 57.45% | |
| P/E | 11.71 | |
| EV/Sales | 3.08 |
5 Analysts have issued a Pfizer forecast for earnings per share. The average Pfizer <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Pfizer stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current Pfizer Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 10 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Dec 18 2024 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 10 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jan 28 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Jan 08 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Dec 18 2024 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Dec 10 2024 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
